The depletion of CD8+ T cells during the establishment of MP-OVA/Riboxxim associated tumor suppression completely abrogated the antitumor response, indicating the indispensability of CD8+ T cells for the effectiveness of PLGA particles as cancer vaccines. The gene discussed is CD8A; the disease is neoplasm.